{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T16:48:02Z","timestamp":1743266882229,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1038\/s41409-022-01734-2","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T17:06:15Z","timestamp":1654794375000},"page":"1451-1454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cure of intravascular NK\/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation"],"prefix":"10.1038","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1908-2096","authenticated-orcid":false,"given":"Julia","family":"Meissner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1579-1509","authenticated-orcid":false,"given":"Michael","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindaugas","family":"Andrulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonille","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Alber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inga","family":"Harting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix T.","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe M.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8570","authenticated-orcid":false,"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"1734_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1365-2141.2004.05177.x","volume":"127","author":"AJ Ferreri","year":"2004","unstructured":"Ferreri AJ, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the \u2018cutaneous variant\u2019. Br J Haematol. 2004;127:173\u201383.","journal-title":"Br J Haematol"},{"key":"1734_CR2","unstructured":"Nakamura S, Ponzoni M, Campo E. Intravascular large B-cell lymphoma. In: Swerdlow SH, Campo E, Pileri AS, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: IARC; 2017. p. 317\u20138."},{"key":"1734_CR3","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/cncr.11107","volume":"97","author":"M Santucci","year":"2003","unstructured":"Santucci M, Pimpinelli N, Massi D, Kadin ME, Meijer CJL, Mueller-Hermelink HK, et al. Cytotoxic\/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer. 2003;97:610\u201327.","journal-title":"Cancer."},{"key":"1734_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5001-6","volume":"18","author":"M Zanelli","year":"2018","unstructured":"Zanelli M, Mengoli MC, Del Sordo R, Cagini A, De Marco L, Simonetti E, et al. Intravascular NK\/T-cell lymphoma, Epstein-Barr virus positive with multiorgan involvement: a clinical dilemma. BMC Cancer. 2018;18:1115.","journal-title":"BMC Cancer"},{"key":"1734_CR5","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1182\/blood-2008-10-185256","volume":"113","author":"W-Y Au","year":"2009","unstructured":"Au W-Y, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, et al. Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113:3931\u20137.","journal-title":"Blood."},{"key":"1734_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05651.x","volume":"130","author":"N Murashige","year":"2005","unstructured":"Murashige N, Kami M, Kishi Y, Kim SW, Takeuchi M, Matsue K, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol. 2005;130:561\u20137.","journal-title":"Br J Haematol"},{"key":"1734_CR7","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1016\/j.bbmt.2018.07.034","volume":"24","author":"SH Jeong","year":"2018","unstructured":"Jeong SH, Song HN, Park JS, Yang DH, Koh Y, Yoon SS, et al. Allogeneic stem cell transplantation for patients with natural killer\/T cell lymphoid malignancy: a multicenter analysis comparing upfront and salvage transplantation. Biol Blood Marrow Transplant. 2018;24:2471\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1734_CR8","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1182\/bloodadvances.2021005899","volume":"8","author":"M Hamadani","year":"2022","unstructured":"Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, et al. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. Blood Adv. 2022;8:920\u201330.","journal-title":"Blood Adv"},{"key":"1734_CR9","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1182\/blood.V89.6.1978","volume":"89","author":"AP Sing","year":"1997","unstructured":"Sing AP, Ambinder RF, Hong DJ, Jensen M, Batten W, Petersdorf E, et al. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin\u2019s disease. Blood. 1997;89:1978.","journal-title":"Blood."},{"key":"1734_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0609.2008.01089.x","volume":"81","author":"N Nakamichi","year":"2008","unstructured":"Nakamichi N, Fukuhara S, Aozasa K, Morii E. NK-cell intravascular lymphomatosis\u2013a mini-review. Eur J Haematol. 2008;81:1\u20137.","journal-title":"Eur J Haematol"},{"key":"1734_CR11","first-page":"2646","volume":"137","author":"N Schmitz","year":"2021","unstructured":"Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Catron G, et al. A randomized phase 3 trial of auto vs allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood. 2021;137:2646\u201356.","journal-title":"Blood"},{"key":"1734_CR12","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/leu.2014.280","volume":"29","author":"A Tanase","year":"2015","unstructured":"Tanase A, Schmitz N, Stein H, Boumendil A, Finel H, Castagna L, et al. Allogeneic and autologous stem cell transplantation for hepatosplenic T cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party. Leukemia. 2015;29:686\u20138.","journal-title":"Leukemia."}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01734-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01734-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01734-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T15:05:18Z","timestamp":1662131118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01734-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1734"],"URL":"https:\/\/doi.org\/10.1038\/s41409-022-01734-2","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"assertion":[{"value":"12 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JM received travel support from BMS, MSD, and Takeda. PD consulted for AbbVie, Allogene Therapeutics, AstraZeneca, bluebird bio, Gilead, Janssen, Novartis, Riemser, and Roche and received compensation. He has received compensation as a member of the speakers bureau for AbbVie, AstraZeneca, Gilead, Novartis, and Riemser. UMM received travel support from Roche, Amgen, and Celgene. MS received research grants from Apogenix, Hexal, and Novartis, travel support from Hexal and Kite as well as financial support for educational activities and conferences from bluebird bio, BMS, Kite\/Gilead, and Novartis. He has received compensation as a member of the scientific advisory board of MSD and GSK. He is Co-Founder and shareholder of TolerogenixX Ltd. MA, LS, SD, BA, IH, FTK, ADH, and CMT declare no potential competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}